1. 賴冠如, 張正雄. JAK2 於骨髓增生性腫瘤的基因診斷與治療知最新發展.
生物醫學. 2011 年第 4 卷第 2 期: 91-99.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22(1):14-22.
3. Office of Rare Diseases Research, US National Insitutes of Health. Genetic and rare disease information center: myelofibrosis [online]. Available from URL:
http://rarediseases.info.nih.gov/GARD/Condition/8618/Myelofibrosis.aspx [Accessed February 05, 2015].
4. Orphanet. Myelofibrosis with myeloid metaplasia [online]. Available from URL: http://www.orpha.net/consor/cgibin/OC_Exp.php?lng=EN&Expert=824 [Accessed February 04, 2015].
5. Girodon F, Bonicelli G, Schaeffer C, Mounier M, Carillo S, Lafon I, Carli PM, Janoray I, Ferrant E, Maynadie M. Significant increase in the apparent
incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica 2009, 94(6):865-869.
6. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997,
15(4):173-189.
7. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E,
Vannucchi AM, Mesa RA, Demory JL, Barosi G et al. New prognostic scoring system for primary myelofibrosis based on a study of the International
Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13):2895-2901.
8. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29(4):392-397.
9. Qureshi MR, MacLean C, McMullin MF, Harrison C. Management of myelofibrosis: a survey of current practice in the United Kingdom. J Clin
Pathol 2012, 65(12):1124-1127.
10. 西藥、醫療器材、含藥化粧品許可證查詢. 行政院衛生福利部食品藥物管 理署. Available from:
http://www.fda.gov.tw/MLMS/(S(fpr21p55kxvkn4rwvqzp0vm2))/H0001D.asp x?Type=Lic&LicId=02023135 [Accessed February 09, 2015].
11. Kantarjian HM, Silver RT, Komrokji RS, et al. Ruxolitinib for
myelofibrosis--an update of its clinical effects. Clin Lymphoma Myeloma Leuk
2013, 13(6):638-645.
12. 西藥、醫療器材、含藥化粧品許可證查詢. 行政院衛生福利部食品藥物管 理署. Available from:
http://www.fda.gov.tw/MLMS/(S(fpr21p55kxvkn4rwvqzp0vm2))/H0001D.asp x?Type=Lic&LicId=52026359 [Accessed February 09, 2015].
13. WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health. Available from:
http://www.whocc.no/atc_ddd_index/ [Accessed February 09, 2015]
14. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012, 366(9):799-807.
15. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366(9):787-798.
16. NICE technology appraisal guidance [TA289]. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis. Available from:
http://www.nice.org.uk/guidance/ta289 [Accessed February 09, 2015].
17. 加拿大腫瘤藥物共同評估組織（pan-Canadian Oncology Drug Review, pCODR). Ruxolitinib for myelofibrosis. Available from:
http://www.pcodr.ca/wcpc/portal/Home/FindaReview/Jakavi?_afrLoop=19126 17824171572&_afrWindowMode=0&_adf.ctrl-state=d34do6ovl_134
[Accessed February 11, 2015].
18. PBAC. Ruxolitinib, tablets, 5 mg, 15 mg and 20 mg, Jakavi® - July 2013.
Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/ruxolitinib [Accessed February 09, 2015]
19. PBAC. Ruxolitinib, tablets, 5 mg, 15 mg and 20 mg, Jakavi® - July 2014.
Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-07/ruxolitinib-psd-07-2014 [Accessed February 09, 2015]
20. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S et al.
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363(12):1117-1127.
21. Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D, Craig D, Woolacott N. Ruxolitinib for the treatment of myelofibrosis: a NICE single
technology appraisal. PharmacoEconomics 2013, 31(10):841-852.
22. Scottish Medicines Consortium. Ruxolitinib (Jakavi). Available from:
https://www.scottishmedicines.org.uk/SMC_Advice/Advice/867_13_ruxolitini b_Jakavi/ruxolitinib_Jakavi [Accessed February 10, 2015]
23. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I [abstract no. 396]. Blood 2013;122(21).
24. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT et al. Three-year efficacy, overall
survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica 2015.
25. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F et al.
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Blood 2013, 122(25):4047-4053.
26. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98(12):1865-1871.
27. Cervantes F, Mesa R, Harrison C. JAK inhibitors: beyond spleen and symptoms? Haematologica 2013, 98(2):160-162.
28. Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. ASH Annual Meeting Abstracts 2012;
120:1733. [Accessed January 02, 2015].
29. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014, 123(12):1833-1835.
30. Vannucchi AM, Hagop K, Kiladjian JJ, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis [abstract no. 2820]. Blood 2013;122(21).
31. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 2013, 161(4):508-516.
32. Verstovsek S, Kiladjian J-J, Mesa RA, et al. Effect of ruxolitinib on the
incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials. ASH Annual Meeting Abstracts 2012; 120:2847. [Accessed January 02, 2015].
33. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011, 365(15):1455-1457.
34. 102 年度全民健康保險醫療統計年報。Available from:
http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=
5327 [Accessed February 10, 2015]
附錄
附錄一、經濟評估文獻搜尋紀錄
資料庫 查詢日期 關鍵字 篇數
PubMed 2015.01.26 1 "ruxolitinib"[All Fields] 311 2 "cost-benefit analysis"[MeSH Terms] OR
"cost-benefit analysis"[tiab] OR ("cost-benefit analysis"[tiab] OR "cost-benefit analysis"[tiab]
OR "costeffectiveness"[tiab] OR "cost
effectiveness"[tiab] OR "cost-utility"[tiab] OR
"cost-minimization"[tiab] OR "economic evaluation"[tiab])
81,374
3 #1AND #2 1
Embase 2015.01.26 1 'ruxolitinib'/exp OR ruxolitinib 1,207 3 (‘cost-benefit analysis’ OR ‘cost-benefit
analysis’ OR ’cost-benefit analysis’
OR ’cost-effectiveness’ OR ’cost effectiveness’
OR ‘cost-utility’ OR ’cost-minimization’ OR
‘economic evaluation’):ti,ab OR ‘economic evaluation’/exp
230,976
5 #1AND #2 16
Cochrane Library
2015.01.26 Ruxolitinib 0